PURE Bioscience, Inc. (PURE) is a Household & Personal Products company in the Consumer Defensive sector, currently trading at $0.07. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Financials: revenue is $2.2B, +37360.4%/yr average growth. Net income is $2M (loss), growing at +10.2%/yr. Net profit margin is -0.1% (negative). Gross margin is 59.2% (+5.2 pp trend).
Balance sheet: total debt is $5.2B with negative equity of -$5.1B — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.12 (adequate). Debt-to-assets is 494.9%. Total assets: $1.1B.
Analyst outlook: 0 / 1 analysts rate PURE as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 25/100 (Fail), Moat 62/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).
